Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Avalo Therapeutics Inc (AVTX)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Avalo Therapeutics's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
12.010 -1.610    -11.82%
18/04 - Closed. Currency in USD ( Disclaimer )
Pre Market
12.050
+0.040
+0.333%
7:00:00 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 104,479
  • Bid/Ask: 11.670 / 12.250
  • Day's Range: 12.000 - 13.760
Avalo Therapeutics 12.010 -1.610 -11.82%

AVTX Ratios

 
Assess the performance of Avalo Therapeutics (AVTX). This table contains core financial ratios such as Price-to-Earnings (P/E ratio), Return-On-Investment (ROI), Earnings per share (EPS), Dividend yield and others based on Avalo Therapeutics Inc's latest financial reports. Compare the performance metrics of Avalo Therapeutics (AVTX) against the industry averages.
InvestingPro Advanced Ratios
Name Company Industry
   
P/E Ratio TTM -0.45 0.72
Price to Sales TTM 7.32 716.27
Price to Cash Flow MRQ -0.46 2.4
Price to Free Cash Flow TTM -0.46 -13.21
Price to Book MRQ 1.93 4.31
Price to Tangible Book MRQ -4.4 1.69
   
Profitability: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Gross margin TTM -417.05% -4,938.09
Gross Margin 5YA -31.15% -983.54
Operating margin TTM -1,218.5% -9,610
Operating margin 5YA -214.84% -2,917.21
Pretax margin TTM -1,638.77% -9,099.6
Pretax margin 5YA -549.94% -1,740.8
Net Profit margin TTM -1,639.5% -9,093.98
Net Profit margin 5YA -1,002.92% -4,772.71
   
Revenue/Share TTM 2.4 38.23
Basic EPS ANN -113.58 7.33
Diluted EPS ANN -113.58 6.96
Book Value/Share MRQ 9.11 63.04
Tangible Book Value/Share MRQ -3.99 47.77
Cash/Share MRQ 9.25 17.5
Cash Flow/Share TTM -38.27 9.15
   
Management Effectiveness: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Return on Equity TTM -863.75% -39.63
Return on Equity 5YA -324.37% -66.96
Return on Assets TTM -116.06% -13.87
Return on Assets 5YA -91.23% -11.93
Return on Investment TTM 0% -8.99
Return on Investment 5YA -102.56% -8.37
   
EPS(MRQ) vs Qtr. 1 Yr. Ago MRQ 95.95% -20.73
EPS(TTM) vs TTM 1 Yr. Ago TTM 89.31% -71.86
5 Year EPS Growth 5YA 0% 6.03
Sales (MRQ) vs Qtr. 1 Yr. Ago MRQ -36.27% 476.19
Sales (TTM) vs TTM 1 Yr. Ago TTM -89.34% 52.24
5 Year Sales Growth 5YA -22.83% 31.23
5 Year Capital Spending Growth 5YA -22.48% 20.56
   
Quick Ratio MRQ 1.61 6
Current Ratio MRQ 1.82 6.34
LT Debt to Equity MRQ - 39.81
Total Debt to Equity MRQ 26.05% 1.98
Efficiency    
Asset Turnover TTM 0.07 0.32
Inventory Turnover TTM 994.8 5.96
Revenue/Employee TTM 101.26K 608.57K
Net Income/Employee TTM -1.66M -401.07K
Receivable Turnover TTM - 6.7
   
Dividend Yield ANN - 0.03
Dividend Yield 5 Year Avg. 5YA - 0.03
Dividend Growth Rate ANN 0% 0.8
Payout Ratio TTM - 1.83
TTM = Trailing Twelve Months  5YA = 5-Year Average  MRQ = Most Recent Quarter
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced valuation and financial ratios for in-depth analysis of company financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

AVTX Comments

Write your thoughts about Avalo Therapeutics Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Rowena Amene farkas
Rowena Amene farkas Mar 29, 2024 10:53AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Ranged
Reply
0 0
Report
Pepe Vega
Pepe Vega Mar 27, 2024 5:09PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Acquisition will cost almost $20 million cash out (mostly to advisors) and huge dilution in future to pay for those first dosages of TRIALS! AND the warrants and stock granted. this over tripling is sbdurdly injustigied and will cost very dearly to those who paid north of 10...
Reply
1 0
Report
AI Kanak
AIKanak Dec 19, 2023 2:54PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Company does not have working a=capital and reverse split wiill slow down liquidity flow. The comoany is doomed. CEO is saying if reverse split is not appo=roved the company will have to sell its property. Which meens inestors will lose thier money. Beware! investors, AVTX is a junk equity. Period!
Reply
0 1
Report
AI Kanak
AIKanak Dec 19, 2023 2:36PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Tomorrow if reverse split gets the votes, then its stock is done for. It will tumble like a pillar of sand. Analyst are already rating it for strong sell. You better take your money and run!
Reply
0 0
Report
Basel haddadin
Basel haddadin Sep 14, 2023 11:35AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
will close at 0.30
Reply
1 4
Report
SS SS
SS SS Jul 21, 2020 6:01PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
any opinion for CERC ? will go up to 5$ soon ?
Reply
2 2
Report
SS SS
SS SS Jun 16, 2020 4:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
any precious idea what will happen with CERC please ?
Reply
1 1
Report
Marco Furlan
Marco Furlan Jun 16, 2020 4:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
They Will have a virtuale encounter with potential investor on 06/ 01/2022, After tomorrow. They probably Will talk about two new drugs they presented FDA , the result of their studies and FDA position. If everithing Is positive the stock might grow .
Reply
0 0
Report
Ubaldo Piazza
Ubaldo Piazza Jun 16, 2020 4:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Tu che ne pensi sarà positivo o no?
Reply
0 0
Report
SS SS
SS SS Jun 13, 2020 3:38AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
is it worths to entry right now ? what do you think folks ?
Reply
0 0
Report
Michael Hobson
Michael Hobson Jul 10, 2017 10:45AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
$5 stock by November 15th, 2017
Reply
0 0
Report
Jeshua Haskins
Jeshua Haskins Jul 10, 2017 10:45AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Possibly more, if they announce good news in conjunction with the positive news they announced earlier this year with CERC-301. FDA already intends to fast track the approval for the MDD drug.
Reply
1 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email